Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ademetionine butanedisulfonate is a stable salt form of S-adenosyl-L-methionine (SAMe), an endogenous amino acid derivative present in virtually all body tissues and fluids. It serves as a primary methyl donor in transmethylation reactions and a precursor for physiological sulfur compounds (such as glutathione, cysteine, taurine, and coenzyme A) via transsulfuration. In the liver, ademetionine regulates hepatocyte membrane fluidity by methylating membrane phospholipids and enhances detoxification by increasing glutathione levels. It is clinically approved for the treatment of intrahepatic cholestasis in pre-cirrhotic and cirrhotic states, intrahepatic cholestasis of pregnancy, and depressive symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ademetionine butanedisulfonate.